9 results about "Mifepristone" patented technology

The invention discloses a Yao medicine composition with effects of regulating menstruation and stopping bleeding as well as a preparation method and application of the Yao medicine composition, and belongs to the technical field of ethnic medicines. The composition is prepared from paris polyphylla, radix zanthoxyli, giantleaf ardisia rhizome, ovateleaf holly bark, radix fici simplicissimae and callicarpa macrophylla. The preparation method comprises the following steps: carrying out secondary water extraction on the raw materials, concentrating to specified density, standing, precipitating, removing impurities, preparing and the like. The Yao medicine composition disclosed by the invention not only has a remarkable hemostatic effect, but also has an excellent endocrine regulation function. Pharmacodynamic experiments show that in a rat dysfunctional blood model induced by combination of mifepristone and misoprostol, the composition can significantly reduce the bleeding amount and shorten the bleeding time, the hemostatic effect is equivalent to that of a positive control drug, namely Gongxuening capsule and a pure paris polyphylla extract, and although a paris polyphylla preparation exists, the hemostatic effect of the composition is remarkably improved. However, the problem that a single paris polyphylla preparation is weak in FSH / LH regulation capacity is solved, and data prove that the compound is irreplaceable.

The present application relates to the use and combination of Shenghua Xinggao and mifepristone in treating embryo residue after medical abortion. The use of Shenghua Xinggao and mifepristone in treating embryo residue after medical abortion can make the blood flow signal of residue disappear and HCG decrease rapidly, thereby greatly reducing the risk of surgical curettage for patients, and has important clinical value.

The present invention relates to the use of the compound mifepristone or a pharmaceutically acceptable salt, solvate or active metabolite thereof at a low dose in the treatment and / or prevention of endometriosis associated pain.

The invention discloses a rodent sterilant synergist and application of the rodent sterilant synergist in preparation of sterilant bait. According to the invention, ketoconazole with relatively strong CYP enzyme inhibitory activity is taken as a synergist and is compounded with mifepristone and baits to form the compound sterilant for harmful rats. Wherein ketoconazole can effectively inhibit the activity of CYP enzyme, significantly reduce the metabolic clearance rate of mifepristone, improve the oral bioavailability of mifepristone, maintain the same sterility prevention and control effect, greatly reduce the use dosage of the sterilant, and realize reduction and synergy. The compound pest sterilant provided by the invention solves the problems of poor killing effect, short lasting effect, fast rebound, high cost, easy generation of drug resistance and accidental killing of natural enemies and non-target organisms in the existing single use of a steroid hormone sterilant, and provides a new solution for sustainable control of pest.

The application provides a composition, a method and application thereof for sows to be delivered at the same time, and particularly discloses a composition and a method for sows to be delivered at the same time by using vitamin B6, mifepristone, combined with sodium cloprostenol and carbetocin to shorten the delivery process and improve the live birth rate. The composition of the application aims at the problem that the live birth rate is reduced due to the sows to be delivered at the same time, thereby affecting the production efficiency of sows, and on the basis of the delivery drugs sodium cloprostenol and carbetocin, vitamin B6 and mifepristone are combined to form a new delivery at the same time scheme. The application shortens the delivery process of sows and improves the live birth rate of sows, and is a method for improving the delivery effect of batch sows at the same time, which provides great value for improving the PSY of sows and promoting the batch management of sows.

The invention discloses a preparation containing mifepristone and a preparation method thereof. The composition comprises quick-release particles and slow-release particles, mifepristone exists in the sustained-release granules in an amorphous form; the weight ratio of the mifepristone in the quick release particles to the mifepristone in the slow release particles is (0.4-2.2): 1; the quick-release particles comprise 5-15% of mifepristone, 45-95% of a filler, 2-20% of a disintegrating agent, 0-2.0% of a lubricant and 0-8% of an adhesive; the sustained-release particles comprise 4.5 to 15 percent of mifepristone and 85 to 95.5 percent of sustained-release auxiliary materials. The sustained-release granules can be continuously released in the intestinal tract, the active ingredients reach a supersaturated state after being released in the intestinal tract, the solubility of the medicine is improved, the medicine is absorbed at the lower end of the small intestine, the supersaturated state can last for more than 4 hours, sufficient time is provided for absorption of the medicine in the intestinal tract, and the bioavailability is remarkably improved. The sustained-release part is not adhered to the intestines and the stomach, has small irritation to the intestines and the stomach, and has no falling risk.

The present invention provides a method for altering the pharmacokinetics of mifepristone upon oral administration. Mifepristone absorption into the blood is increased upon administration with meals. The method of the invention can benefit patients suffering from conditions including psychiatric illnesses and hormonal disorders.

The application discloses a maternal-fetal interface immune function regulator and belongs to the technical field of medicines. An effective component of the maternal-fetal interface immune function regulator comprises any one of tarazepide, mifepristone, L-canavanine or butaprost or a pharmaceutically acceptable salt thereof. The maternal-fetal interface immune function regulator is administered during pregnancy. By activating a positive feedback loop COX-2 / PGE2 / PTGER-2, up-regulating placental IDO-1 expression and regulating the steady-state recovery of placental tryptophan metabolism, the maternal-fetal interface immune function regulator promotes the recovery of the maternal-fetal interface immune steady state, improves the maternal-fetal barrier function, improves the development of neurons in the brain of offspring and prevents the neurological development disorder of offspring. The use of the maternal-fetal interface immune function regulator during pregnancy can be applied as a new means for treating the neurological development disorder of offspring, and provides a new experimental basis and treatment idea for the treatment of autism in clinical practice.

Safe and effective methods for treating a subject suffering from cortisol excess of and in need of concomitant administration of mifepristone along with a CYP3A4 inducer are disclosed herein. The CYP3A4 inducer may be, for example, mitotane, rifampin (also known as rifampicin), rifabutin, rifapentin, phenobarbital, phenytoin, carbamazepine, or St. John's wort. In embodiments, the CYP3A4 inducer is a strong CYP3A4 inducer. In embodiments, the CYP3A4 inducer is a moderate CYP3A4 inducer. In embodiments, the CYP3A4 inducer may be any CYP3A4 inducer. Mifepristone may be orally administered. Mifepristone may be administered with food.